Navigation Links
New protein inhibitor impedes growth of cancerous cells

Researchers have developed a small-molecule inhibitor of a protein that plays key roles in the control of cell division, and they show that the inhibitor can halt the growth of tumors in mice and cancer-derived cells growing in culture. The findings are reported in companion papers reported by two collaborating groups—one (Lenart et al.) led by Jan-Michael Peters of the Research Institute of Molecular Pathology in Vienna, and the other (Steegmaier et al.) led by Norbert Kraut of Boehringer Ingelheim Austria GmbH. The papers will appear in Current Biology online on February 8th.

Because cancer cells are typically fast growing and can mutate to adapt to new growth conditions, effective drug-based therapies will likely succeed in part by impeding multiple functions required for cell division and survival. One particular class of proteins, known as kinases, is known to play especially critical roles in the division of healthy cells, and appears to also be important for cell division in cancer cells, even though these cells are diseased and have lost some of the restraints on division that normal cells impose on themselves. Because central aspects of cell division are under the control of just a few key kinases, these proteins represent potentially important targets for new cancer therapeutics, but few if any effective inhibitors have been identified as acting specifically and effectively against one particular cell-division kinase, known as Plk1.

In the new work, Steegmaier et al. isolated a chemical compound, which they term BI 2536, that they demonstrate to be a potent inhibitor of Plk1, and show that BI 2536 can indeed effectively halt the growth of cancerous cells, both in cell culture and in an animal model for human tumor growth. BI 2536 caused growth arrest and cell death in cell lines derived from a variety of human cancers, and it inhibited the growth of human tumor grafts in mice, resulting in the death of tumor cells and regression of large t umors. The authors report that BI 2536 has now been brought into use in clinical studies of patients with locally advanced or metastatic cancers in order to address the therapeutic potential of the compound.

In the companion paper, Lenart et al. use BI 2536 as a tool to probe the functions of Plk1 in normal cells. The availability of a specific Plk1 inhibitor is particularly useful in this regard because Plk1 is needed for a variety of different cellular processes required for cell division, and a chemical inhibitor such as BI 2536 allows Plk1 function to be experimentally disrupted at specific points during the cell-division cycle, thereby revealing the normal roles of Plk1 in new detail, and potentially identifying specific cellular processes that might be targeted by future anti-cancer therapeutics.
'"/>

Source:Cell Press


Related biology news :

1. New, automated tool successfully classifies and relates proteins in unprecedented way
2. New binding target for oncogenic viral protein
3. Controversial drug shown to act on brain protein to cut alcohol use
4. Timing is everything: First step in protein building revealed
5. UWs Rosetta software to unlock secrets of many human proteins
6. Researchers find how protein allows insects to detect and respond to pheromones
7. Signaling protein builds bigger, better bones in mice
8. Ancient olfaction protein is shared by many bugs, offering new pest control target
9. Automatic extraction of gene/protein biological functions from biomedical text
10. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
11. Scientists develop new color-coded test for protein folding

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
(Date:6/23/2016)... 23, 2016 ReportsnReports.com adds ... to its pharmaceuticals section with historic and forecast ... much more. Complete report on the ... profiling 15 companies and supported with 261 tables ... . The Global Cell Culture ...
Breaking Biology Technology: